PureTech Health (PRTC) announced that the U.S. Food and Drug Administration has granted Fast Track designation to LYT-200, a ...
Biotherapeutics company PureTech Health plc (PRTC) announced Thursday that the U.S. Food and Drug Administration (FDA) has granted ...
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today ...
About PureTech Health PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company ...
The biotherapeutics company said the treatment, LYT-200, is being evaluated in two ongoing clinical trials. It was previously granted orphan drug designation for the treatment of acute myeloid ...
(Alliance News) - PureTech Health PLC on Thursday said that the US Food & Drug Administration has granted fast track designation to its antibody LYT-200 for the treatment of acute myeloid leukemia.
Shares of PureTech Health plc (NASDAQ:PRTC – Get Free Report) were down 6.3% on Thursday . The stock traded as low as $17.04 and last traded at $17.55. Approximately 6,778 shares traded hands during ...
GET MORE AI-GENERATED SIGNALS: January 10, 2025, 20:42 pm ET, BY Rick W.- Contributor| Editor: Thomas H. Kee Jr. ( Follow on LinkedIn) Short PRTC slightly under 20.06, target 16.8, stop loss @ 20.12 ...
BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), is pleased to announce that it has appointed UBS as its UK Corporate Broker.
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), is pleased to announce that it has appointed UBS as its UK Corporate Broker. About PureTech Health PureTech is a ...
PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and ...